Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Dapagliflozin/Metformin XR Manufactured at Two Different Plants
NCT02637037Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin and metformin in type 2 diabetes mellitus (T2DM) (8 arms), sponsored by AstraZeneca. Primary endpoints: Area Under Plasma Concentration-time Curve, AUC From Time Zero to Time of Last Quantifiable Concentration and 1 more. Started Dec 2015; status: completed.
02
Drugs
dapagliflozinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02637037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02637037.